The 2VAL Study: A trial comparing the effect of valacyclovir and valganciclovir prophylaxis against cytomegalovirus (CMV) infection after renal transplantatio

Phase 4

Completed

• Conditions: Cytomegalovirus infection after renal transplantation; Infection - Studies of infection and infectious agents; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12610000016033
• Lead Sponsor: Tomas Reischig, M.D., Ph.D.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-09-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 114

Inclusion Criteria

Recipients of transplant from deceased or living donor, known donor (D) and recipient (R) CMV serology before transplantation of D+/R- or D+/R+ or D-/R+, provided informed consent

Exclusion Criteria

Unknown or D-/R- CMV serology prior to transplantation, systemic antiviral drug intake within 2 weeks before transplantation except for hepatitis B therapy (lamivudine, adefovir, entecavir), active viral infection at the time of transplantation (except for hepatitis B or C), significant leukopenia or thrombocytopenia, participation in another clinical trial, known allergy to (val)acyclovir or (val)ganciclovir, inability to provide informed concent

Study & Design

• Study Type: Interventional
• Study Design: Not specified